About Lasa Supergenerics Limited
Data last updated: 23 December 2025
Lasa Supergenerics Limited is a public limited company based in Khed, Maharashtra, India, a subsidiary of Omkar Speciality Chemicals Limited. It specialises in animal pharmaceuticals and healthcare, a part of the broader pharmaceuticals sector. Incorporated on 11 March 2016, the company has been in operation for over 10 years.
Registered with ROC Mumbai under CIN U24233MH2016PLC274202. Listed on BSE: 540702 and NSE: LASA.
Capital: an authorised share capital of ₹100.33 Cr and a paid-up capital of ₹50.1 Cr. It is led by directors including Manali Roop Bhagtani and Umesh Shankar Pawar.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Khed, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹147.46 Cr, a growth of 41% compared to the previous year.
The company has a workforce of approximately 326 employees as per the latest available data. It operates as a subsidiary of Omkar Speciality Chemicals Limited.
As per MCA filings, the company has satisfied charges of ₹84.64 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lasalabs.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressPlot No. C – 4 C – 4/1 Midc Lote Parshuram Industrial Area Tal – Khe, D, Khed, Maharashtra, India – 415722
-
IndustryPharma, Animal Pharmaceuticals & Healthcare
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Lasa Supergenerics Limited
Lasa Supergenerics Limited has one previous CIN (Corporate Identification Number): U24233MH2016PLC274202. The current CIN is L24233MH2016PLC274202, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24233MH2016PLC274202 | Current |
| U24233MH2016PLC274202 | Previous |
Business Activity of Lasa Supergenerics Limited
Lasa Supergenerics Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Lasa Supergenerics Limited
Lasa Supergenerics Limited is audited by Gupta Rustagi & Co (ICAI peer reviewed, certificate valid till 2028-02-29) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Gupta Rustagi & Co (ICAI peer reviewed, certificate valid till 2028-02-29) | FY 2026 | Statement on impact of audit qualification |
Board of Directors of Lasa Supergenerics Limited
Lasa Supergenerics Limited is currently managed by 14 directors, with 20 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manali Roop Bhagtani | Director | 15 May 2018 | 8 Years 1 Months | Current |
| Umesh Shankar Pawar | Whole-Time Director | 08 Mar 2024 | 2 Years 4 Months | Current |
| Hardesh Raja Tolani | Director | 02 May 2017 | 9 Years 2 Months | Current |
| Ekta Avtar Gurnasinghani | Director | 02 May 2017 | 9 Years 2 Months | Current |
|
Omkar Herlekar Pravin
Also directs:
Lasa Lifesciences Private Limited, Dr. Omkar Herlekar Foundation
|
Managing Director | 11 Mar 2016 | 10 Years 3 Months | Current |
| Ajay Hareshlal Sukhwani | Director | 02 May 2017 | 9 Years 2 Months | Current |
Financials of Lasa Supergenerics Limited FY 2026 filings available
Lasa Supergenerics Limited reported revenue of ₹25.14 Cr (down 82.35% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹25.14 Cr | ₹142.45 Cr | ₹104.34 Cr | ₹129.57 Cr | ₹137.13 Cr | ₹202.38 Cr | ₹167.27 Cr |
| Other Income | ₹19.98 Lakh | ₹5.01 Cr | ₹9.93 Lakh | ₹1.8 Cr | ₹5.74 Lakh | ₹5.76 Lakh | ₹23.16 Lakh |
| Total Income | ₹25.34 Cr | ₹147.46 Cr | ₹104.43 Cr | ₹131.37 Cr | ₹137.18 Cr | ₹202.44 Cr | ₹167.5 Cr |
| Cost of Materials Consumed | ₹19.15 Cr | ₹108.1 Cr | ₹79.28 Cr | ₹110.12 Cr | ₹88.21 Cr | ₹102.11 Cr | ₹86.51 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹6.25 Cr | ₹0 | ₹49.41 Lakh |
| Changes in Inventories | ₹4.69 Cr | -₹1.91 Cr | -₹4.06 Cr | -₹4.01 Cr | -₹3.17 Cr | ₹10.24 Cr | ₹7.65 Cr |
| Employee Benefit Expense | ₹2.17 Cr | ₹6.11 Cr | ₹6.34 Cr | ₹7.37 Cr | ₹9.93 Cr | ₹14.01 Cr | ₹13.42 Cr |
| Finance Costs | ₹38.62 Lakh | ₹2.69 Cr | ₹1.93 Cr | ₹4.16 Cr | ₹4.03 Lakh | ₹1.96 Cr | ₹8.1 Cr |
| Depreciation & Amortisation | ₹6.02 Cr | ₹12.3 Cr | ₹10.67 Cr | ₹13.42 Cr | ₹14 Cr | ₹15.82 Cr | ₹17.34 Cr |
| Other Expenses | ₹27.53 Cr | ₹23.89 Cr | ₹20.61 Cr | ₹22.68 Cr | ₹20.27 Cr | ₹28.8 Cr | ₹29.25 Cr |
| Total Expenses | ₹59.95 Cr | ₹151.17 Cr | ₹114.77 Cr | ₹153.74 Cr | ₹135.53 Cr | ₹172.95 Cr | ₹162.77 Cr |
| Profit Before Exceptional Items & Tax | -₹34.61 Cr | -₹3.71 Cr | -₹10.34 Cr | -₹22.37 Cr | ₹1.65 Cr | ₹29.49 Cr | ₹4.74 Cr |
| Exceptional Items | ₹0 | -₹15.67 Cr | -₹8.77 Cr | -₹19.9 Cr | -₹7.86 Cr | ₹0 | ₹0 |
| Profit Before Tax | -₹34.61 Cr | -₹19.38 Cr | -₹19.11 Cr | -₹42.27 Cr | -₹6.21 Cr | ₹29.49 Cr | ₹4.74 Cr |
| Total Tax Expense | -₹51.74 Lakh | -₹4.63 Cr | ₹2.62 Cr | -₹3.69 Cr | -₹1.46 Cr | ₹7.62 Cr | ₹74.02 Lakh |
| Net Profit | -₹34.09 Cr | -₹14.76 Cr | -₹21.73 Cr | -₹38.62 Cr | -₹5.37 Cr | ₹22.78 Cr | ₹3.63 Cr |
| Other Comprehensive Income | ₹0 | ₹4.42 Lakh | ₹11.54 Lakh | ₹3.91 Lakh | ₹6.1 Lakh | ₹0 | ₹3.95 Lakh |
| Total Comprehensive Income | -₹34.09 Cr | -₹14.71 Cr | -₹21.62 Cr | -₹38.58 Cr | -₹5.31 Cr | ₹22.78 Cr | ₹3.67 Cr |
| EBITDA (computed) | -₹28.2 Cr | ₹11.28 Cr | ₹2.27 Cr | -₹4.79 Cr | ₹15.69 Cr | ₹47.28 Cr | ₹30.18 Cr |
| Basic EPS | ₹-6.80 | ₹-2.95 | ₹-4.34 | ₹-7.71 | ₹-1.32 | ₹5.60 | ₹1.26 |
| Diluted EPS | ₹-6.80 | ₹-2.95 | ₹-4.34 | ₹-7.71 | ₹-1.32 | ₹5.60 | ₹1.26 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹66.27 Cr | ₹101.53 Cr | ₹150.87 Cr | ₹163.85 Cr |
| Non-current Assets | ₹55.83 Cr | ₹69.02 Cr | ₹112.98 Cr | ₹124.63 Cr |
| Current Assets | ₹10.44 Cr | ₹32.51 Cr | ₹37.89 Cr | ₹39.22 Cr |
| Property, Plant & Equipment | ₹38.38 Cr | ₹48.09 Cr | ₹83.82 Cr | ₹88.13 Cr |
| Inventories | ₹1.82 Cr | ₹24.5 Cr | ₹19.04 Cr | ₹13.9 Cr |
| Trade Receivables | ₹4.12 Lakh | ₹1.49 Cr | ₹3.59 Cr | ₹2.48 Cr |
| Cash & Equivalents | ₹28.78 Lakh | ₹27.53 Lakh | ₹60.86 Lakh | ₹79.95 Lakh |
| Equity (Net Worth) | ₹49.62 Cr | ₹83.71 Cr | ₹96.68 Cr | ₹118.29 Cr |
| Equity Share Capital | ₹50.1 Cr | ₹50.1 Cr | ₹50.1 Cr | ₹50.1 Cr |
| Borrowings (Non-current) | ₹0 | ₹44.22 Lakh | ₹0 | ₹0 |
| Borrowings (Current) | ₹9.75 Cr | ₹2.13 Cr | ₹22.08 Cr | ₹0 |
| Total Debt (computed) | ₹9.75 Cr | ₹2.57 Cr | ₹22.08 Cr | ₹0 |
| Current Liabilities | ₹16.77 Cr | ₹17.15 Cr | ₹48.87 Cr | ₹42.73 Cr |
| Total Liabilities | ₹16.65 Cr | ₹17.82 Cr | ₹54.19 Cr | ₹45.57 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹22.83 Cr | -₹2.82 Cr | ₹2.14 Cr | -₹33.51 Cr | ₹10.49 Cr |
| Investing Cash Flow | ₹0 | ₹8.15 Cr | -₹39.78 Lakh | ₹1.53 Cr | -₹3.25 Cr |
| Financing Cash Flow | ₹0 | -₹5.66 Cr | -₹1.93 Cr | ₹4.16 Cr | -₹4.03 Lakh |
| Capital Expenditure | ₹0 | ₹0 | -₹66.08 Lakh | ₹4.83 Cr | -₹2.28 Cr |
| Free Cash Flow (computed) | -₹22.83 Cr | -₹2.82 Cr | ₹1.48 Cr | -₹38.34 Cr | ₹8.21 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹22.83 Cr | -₹33.33 Lakh | -₹19.14 Lakh | -₹27.02 Cr | ₹7.2 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | -₹13.15 Lakh | ₹2.2 Cr | ₹3.06 Cr | ₹20.01 Cr | ₹39.14 Cr | ₹33.08 Cr | ₹39.39 Cr | ₹30.84 Cr | ₹22.82 Cr | ₹26.66 Cr | ₹24.3 Cr | ₹30.56 Cr |
| Other Income | ₹4.07 Lakh | ₹1.79 Lakh | ₹70,000 | ₹13.42 Lakh | ₹2.39 Cr | ₹14.21 Lakh | ₹1.95 Cr | ₹47,000 | ₹79,000 | ₹36,000 | ₹8.4 Lakh | ₹39,000 |
| Total Income | -₹9.08 Lakh | ₹2.22 Cr | ₹3.07 Cr | ₹20.15 Cr | ₹41.53 Cr | ₹33.22 Cr | ₹41.34 Cr | ₹30.84 Cr | ₹22.82 Cr | ₹26.66 Cr | ₹24.39 Cr | ₹30.56 Cr |
| Cost of Materials Consumed | ₹66.83 Lakh | ₹48.77 Lakh | ₹4.33 Cr | ₹13.66 Cr | ₹31.68 Cr | ₹25.83 Cr | ₹30.28 Cr | ₹20.3 Cr | ₹19.04 Cr | ₹18.39 Cr | ₹19.65 Cr | ₹22.2 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹30.48 Lakh | ₹1.77 Cr | ₹1.2 Cr | ₹2.03 Cr | -₹3.36 Cr | -₹1.32 Cr | ₹1 Cr | ₹1.76 Cr | -₹56.06 Lakh | ₹1.54 Cr | -₹3.14 Cr | -₹1.9 Cr |
| Employee Benefit Expense | ₹4.65 Lakh | ₹16.35 Lakh | ₹78.27 Lakh | ₹1.18 Cr | ₹1.43 Cr | ₹1.47 Cr | ₹1.59 Cr | ₹1.62 Cr | ₹1.51 Cr | ₹1.55 Cr | ₹1.59 Cr | ₹1.69 Cr |
| Finance Costs | ₹12.86 Lakh | ₹11.2 Lakh | ₹11.95 Lakh | ₹2.6 Lakh | ₹10.77 Lakh | ₹47.21 Lakh | ₹1.24 Cr | ₹87.15 Lakh | ₹56.02 Lakh | ₹44.1 Lakh | ₹55.76 Lakh | ₹37.32 Lakh |
| Depreciation & Amortisation | ₹1.31 Cr | ₹1.57 Cr | ₹1.57 Cr | ₹1.57 Cr | ₹3.9 Cr | ₹2.8 Cr | ₹2.81 Cr | ₹2.79 Cr | ₹2.66 Cr | ₹2.68 Cr | ₹2.68 Cr | ₹2.65 Cr |
| Other Expenses | ₹2.04 Cr | ₹52.4 Lakh | ₹74.47 Lakh | ₹3.65 Cr | ₹5.97 Cr | ₹6.3 Cr | ₹5.73 Cr | ₹5.35 Cr | ₹6.81 Cr | ₹4.13 Cr | ₹5.16 Cr | ₹4.51 Cr |
| Total Expenses | ₹3.89 Cr | ₹4.63 Cr | ₹8.75 Cr | ₹22.11 Cr | ₹39.73 Cr | ₹35.56 Cr | ₹42.66 Cr | ₹32.7 Cr | ₹30.02 Cr | ₹28.73 Cr | ₹26.5 Cr | ₹29.53 Cr |
| Profit Before Exceptional Items & Tax | -₹3.98 Cr | -₹2.41 Cr | -₹5.68 Cr | -₹1.96 Cr | ₹1.8 Cr | -₹2.34 Cr | -₹1.31 Cr | -₹1.86 Cr | -₹7.19 Cr | -₹2.06 Cr | -₹2.11 Cr | ₹1.03 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | -₹20.57 Cr | -₹23.91 Cr | ₹8.25 Cr | ₹0 | ₹0 | -₹8.77 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹3.98 Cr | -₹2.41 Cr | -₹5.68 Cr | -₹22.54 Cr | -₹22.12 Cr | ₹5.91 Cr | -₹1.31 Cr | -₹1.86 Cr | -₹15.97 Cr | -₹2.06 Cr | -₹2.11 Cr | ₹1.03 Cr |
| Total Tax Expense | ₹18.76 Lakh | ₹14.31 Lakh | ₹57.12 Lakh | -₹1.42 Cr | -₹7.83 Cr | ₹41.58 Lakh | ₹1.92 Cr | ₹86.85 Lakh | -₹66.74 Lakh | -₹60.59 Lakh | -₹2.09 Cr | ₹5.98 Cr |
| Net Profit | -₹4.16 Cr | -₹2.55 Cr | -₹6.25 Cr | -₹21.12 Cr | -₹14.29 Cr | ₹5.49 Cr | -₹3.23 Cr | -₹2.73 Cr | -₹15.3 Cr | -₹1.46 Cr | -₹2.29 Lakh | -₹4.95 Cr |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹4.42 Lakh | ₹0 | ₹0 | ₹0 | ₹11.54 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹4.16 Cr | -₹2.55 Cr | -₹6.25 Cr | -₹21.12 Cr | -₹14.25 Cr | ₹5.49 Cr | -₹3.23 Cr | -₹2.73 Cr | -₹15.18 Cr | -₹1.46 Cr | -₹2.29 Lakh | -₹4.95 Cr |
| EBITDA (computed) | -₹2.54 Cr | -₹72.97 Lakh | -₹3.99 Cr | -₹36.82 Lakh | ₹5.8 Cr | ₹93.24 Lakh | ₹2.74 Cr | ₹1.8 Cr | -₹3.97 Cr | ₹1.06 Cr | ₹1.13 Cr | ₹4.05 Cr |
| Basic EPS | ₹-0.83 | ₹-0.51 | ₹-1.25 | ₹-4.22 | ₹-2.85 | ₹1.10 | ₹0.64 | ₹0.55 | ₹-3.05 | ₹-0.29 | ₹0.00 | ₹-0.99 |
| Diluted EPS | ₹-0.83 | ₹-0.51 | ₹-1.25 | ₹-4.22 | ₹-2.85 | ₹1.10 | ₹0.64 | ₹0.55 | ₹-3.05 | ₹-0.29 | ₹0.00 | ₹-0.99 |
Board & Governance of Lasa Supergenerics Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Lasa Supergenerics Limited has 6 directors - 4 independent and 2 executive. The board is chaired by Omkar Pravin Herlekar.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Omkar Pravin Herlekar | Executive Director · MD · Chairperson | 2016-03-11 | 1 |
| Ganesh Suresh Potdar | Executive Director · MD | 2026-01-02 | 1 |
| Ketan Bhau Songal | Non-Executive - Independent Director | 2025-08-04 | 1 |
| Pravin Gadalya Lachake | Non-Executive - Independent Director | 2025-08-04 | 1 |
| Yogesh Hari Ughada | Non-Executive - Independent Director | 2025-08-04 | 1 |
| Rekha Hemant Wakh | Non-Executive - Independent Director | 2025-08-04 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Ketan Bhau Songal (Chairperson), Rekha Hemant Wakh, Omkar Pravin Herlekar |
| Nomination and remuneration committee | Ketan Bhau Songal (Chairperson), Rekha Hemant Wakh, Pravin Gadalya Lachake |
| Stakeholders Relationship Committee | Pravin Gadalya Lachake (Chairperson), Yogesh Hari Ughada, Omkar Pravin Herlekar |
| Corporate Social Responsibility Committee | Pravin Gadalya Lachake (Chairperson), Omkar Pravin Herlekar, Yogesh Hari Ughada |
| Enquiry Committee | Omkar Pravin Herlekar (Chairperson), Ketan Bhau Songal, Pravin Gadalya Lachake |
| Advisory Committee | Omkar Pravin Herlekar (Chairperson), Ketan Bhau Songal, Rekha Hemant Wakh |
| Fund Raising Committee | Omkar Pravin Herlekar (Chairperson), Ketan Bhau Songal, Yogesh Hari Ughada, Pravin Gadalya Lachake |
Charges & Borrowings of Lasa Supergenerics Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Apr 2018 | Others | ₹6.03 Cr | Satisfied |
| 31 Mar 2018 | Others | ₹1.82 Cr | Satisfied |
| 28 Nov 2012 | Axis Bank Limited | ₹76.79 Cr | Satisfied |
Total charge records: 3 View all charges
Employees and EPFO Compliance at Lasa Supergenerics Limited
View historical data on people associated with Lasa Supergenerics Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Lasa Supergenerics Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Lasa Supergenerics Limited
GSTIN & GST Filing Data of Lasa Supergenerics Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Lasa Supergenerics Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Lasa Supergenerics Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Lasa Supergenerics Limited
MSME Payment Delays by Lasa Supergenerics Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Lasa Supergenerics Limited
Subsidiaries & Group Companies of Lasa Supergenerics Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Lasa Supergenerics Limited with ownership details.
MCA Filings & Documents of Lasa Supergenerics Limited
MCA Filings & Documents of Lasa Supergenerics Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Lasa Supergenerics Limited
Recent News on Lasa Supergenerics Limited
Frequently Asked Questions about Lasa Supergenerics Limited
Lasa Supergenerics Limited is an active public limited company in the pharma sector based in Khed, Maharashtra, India. It was incorporated on 11 March 2016 (10+ years old) and is registered under CIN L24233MH2016PLC274202. Listed on BSE: 540702 and NSE: LASA. The company has 326 employees.
Lasa Supergenerics Limited reported revenue of ₹147.46 Cr for FY 2025 (up 41.00% YoY).
The current directors of Lasa Supergenerics Limited are:
- Manali Roop Bhagtani
- Umesh Shankar Pawar
- Mitti Jain
- Hardesh Raja Tolani
- Ekta Avtar Gurnasinghani
- Omkar Herlekar Pravin
- Ajay Hareshlal Sukhwani
- Mitti Mitesh Jain
- Prathmesh Prakash Chalke
- Varsha Pravin Joshi
- Ketan Bhau Songal
- Pravin Gadalya Lachake
- Yogesh Hari Ughada
- Rekha Hemant Wakh
The primary industry of Lasa Supergenerics Limited is pharma. The company specifically operates in animal pharmaceuticals and healthcare. The company is currently active in this sector.
Yes. Lasa Supergenerics Limited is listed on both BSE (code: 540702) and NSE (symbol: LASA).
Lasa Supergenerics Limited can be reached at the registered office: Plot No. C – 4 C – 41 Midc Lote Parshuram Industrial Area Tal – Khe, D, Khed, Maharashtra, India – 415722, or through the website lasalabs.com.